Investigational Drug Information for LOU064
✉ Email this page to a colleague
What is the development status for investigational drug LOU064?
LOU064 is an investigational drug.
There have been 17 clinical trials for LOU064.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2021.
The most common disease conditions in clinical trials are Urticaria, Chronic Urticaria, and Multiple Sclerosis. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are eleven US patents protecting this investigational drug and two hundred and thirty-nine international patents.
Summary for LOU064
| US Patents | 11 |
| International Patents | 239 |
| US Patent Applications | 96 |
| WIPO Patent Applications | 47 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2021-11-30) |
| Vendors | 37 |
Recent Clinical Trials for LOU064
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Novartis Pharmaceuticals | Phase 3 |
| A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. | Novartis Pharmaceuticals | Phase 3 |
| 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Y | Novartis Pharmaceuticals | Phase 3 |
Clinical Trial Summary for LOU064
Top disease conditions for LOU064
Top clinical trial sponsors for LOU064
US Patents for LOU064
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LOU064 | ⤷ Sign Up | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Treatment of cancer using a CLL-1 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Treatment of cancer using a CD123 chimeric antigen receptor | The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Treatment of cancer using GFR .alpha.-4 chimeric antigen receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) NOVARTIS AG (Basel, CH) THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Antibody molecules to PD-L1 and methods of treating cancer | Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) President and Fellows of Harvard College (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LOU064
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LOU064 | Argentina | AR102035 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Australia | AU2015292744 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Australia | AU2020202726 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Brazil | BR112017001183 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Canada | CA2955386 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | China | CN106687483 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Colombia | CO2017000507 | 2034-07-21 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
